Skip to content
mapperlab
← Dashboard
Stock

ATRC

AtriCure, Inc.
Latest close $287 of 27 marquee funds currently hold1 CUSIP mapped
Current holders
7
27 funds tracked
Ever held
9
Current + past
New this quarter
2
Exited this quarter
1

Marquee-fund ownership over time

May 17, 2021Aug 9, 2024Aug 14, 2025May 15, 2026
Now
7

This quarter's activity

New positions opened

Positions exited

Current holders

Sorted by tenure (longest first)
FundEntry priceLatest closeReturn on entry
Bridgewater Associates re-entered$73$28-61%
Renaissance Technologies$21$28+36%
Citadel Advisors$23$28+26%
Two Sigma Investments$23$28+26%
D.E. Shaw re-entered$23$28+26%
AQR Capital Management$23$28+26%
Millennium Management$23$28+26%

“Return on entry” is the price-only move from the fund's first disclosure to today — it ignores any adds, trims, or dividends. A fund that built its position over multiple quarters has a true cost basis somewhere between entry price and latest close; this figure is the upper bound.

Past holders

Funds that exited at some point
FundEntry → ExitReturn
Point72 Asset Management 2× in & out→ $28-15%
Maverick Capital→ $75+3%

Insider activity

Form 4 — officers, directors, 10%+ owners

Filed within two business days of each transaction by anyone with material insider status at AtriCure, Inc.. Pair with the holders table above as a sanity check: heavy insider buying alongside marquee-fund accumulation is the strongest accumulation signal; heavy insider selling alongside fund exits is the strongest distribution signal.

Filings · last 30d
10
Filings · last 90d
20
Total on file
585
Recent SEC buffer
Most recent
May 22, 2026

30d / 90d windows measured from May 22, 2026 — the most recent Form 4 on file — not from today.

Showing 15 of 585 recent Form 4 filings. Browse all on EDGAR ↗

Fundamentals

XBRL · AtriCure, Inc.

Annual figures sourced directly from AtriCure, Inc.'s 10-K / 10-Q filings via SEC EDGAR XBRL. Latest fiscal year and the year-over-year change, with up to ten years of history.

Revenue
$534.53M
FY2025+15% YoY
Net income
-$11.45M
FY2025+74% YoY
EPS (diluted)
$-0.2400
FY2025+75% YoY
Free cash flow(?)
$48.28M
FY2025+500%+ YoY

Recent SEC filings

10-K · 10-Q · 8-K · 13D/G · proxy

The most recent material filings for AtriCure, Inc. — earnings, material events, ownership disclosures, proxy statements. Form 4 insider activity is shown in the panel above.

Trade history

Every open→close lifecycle across tracked funds
FundOpen dateClose dateOpen priceClose price / currentReturn
Bridgewater AssociatesQ2 2026open$28$26-8%
D.E. ShawQ2 2026open$28$28+1%
Point72 Asset ManagementQ1 2026Q2 2026$33$28-15%
Point72 Asset ManagementQ2 2025Q3 2025$32$35+10%
Citadel AdvisorsQ3 2024open$23$28+26%
Two Sigma InvestmentsQ3 2024open$23$28+26%
D.E. ShawQ3 2024Q4 2025$23$33+46%
AQR Capital ManagementQ3 2024open$23$28+26%
Millennium ManagementQ3 2024open$23$28+26%
Renaissance TechnologiesQ3 2024open$21$28+36%
Bridgewater AssociatesQ3 2021Q1 2025$73$40-46%
Maverick CapitalQ2 2021Q4 2021$73$75+3%
Caveats
  • Covers only the 27 marquee funds tracked here, not the full institutional universe. A “0 holders” reading does not mean unowned.
  • Heavy funds (Renaissance Technologies, Citadel Advisors, Soros Fund Management, Two Sigma Investments, D.E. Shaw, AQR Capital Management, Millennium Management, Point72 Asset Management) use 8-quarter snapshots, so their pre-2024 history is missing.
  • “Current” reflects each fund's most recent 13F — filings lag the actual trade by up to 45 days; positions shown may have changed since.
  • Cost = price at the entry filing date. Re-entered positions show the most recent open lot.
  • Options, ADRs, and unmapped CUSIPs are excluded from the follower-backtest pipeline that produces these snapshots, so certain holding types won't appear here.